<DOC>
	<DOCNO>NCT01283425</DOCNO>
	<brief_summary>The study open-label , randomize , two-period crossover study . Up one hundred twenty ( 120 ) subject type 1 diabetes mellitus ( T1DM ) use MiniMed paradigm insulin pump , meet inclusion/exclusion criterion provide write Informed Consent enrol study . The aim study examine safety InsuPatch device home use set . Mild Hypoglycemia , hyperglycemia Adverse event compare two phase study : 3 month use device 3 month without use device .</brief_summary>
	<brief_title>Evaluation Safety Use InsuPatch Device Daily Life Conditions</brief_title>
	<detailed_description>The primary objective study show safety parameter similar , deliver insulin subcutaneously subject type I diabetes use InsuPatch device along Medtronic Minimed Paradigm insulin infusion pump Medtronic Minimed Quick-SetÂ® infusion set compare subcutaneous insulin deliver mentioned equipment , without InsuPatch device . The participation subject study seven month include three phase : one week Run phase , 3 month device use 3 month without device use . Study include 4 clinic visit bi weekly call . During entire study subject request preform least 5 blood glucose self measurement record result logbook.At visit blood drawn HBA1C test .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Subject 's age range 18 65 year old ( include 18 65 year old ) 2 . BMI : 1835 kg/m2 3 . Type 1 diabetes patient use MiniMed Paradigm insulin pump least six month , administer insulin Lispro Insulin Aspart use Quickset infusion set . 4 . Patients T1DM whose HbA1c value 9.5 % ( include 9.5 % ) 6 % ( include 6 % ) . 5 . Agree sign consent form studyspecific test procedure perform . 6 . Subject 's complete least 14 measurement RunIn Phase readiness continue study least 5 blood glucose recording per day keep logbook study period . 7 . Subject readiness use InsuPatch , comprehension study requirement treatment procedure . 8 . Willingness comply specify followup evaluation . 1 . Pregnancy 2 . Breast feeding woman . 3 . Alcohol addiction 4 . CABG ( Coronary Artery Bypass Graft ) , MI ( Myocardial Infarction ) active Ischemic Heart Disease prior study date . 5 . CVA ( cardiovascular accident ) TIA ( transient ischemic accident ) event prior study date . 6 . Uncontrolled hypertension ( blood pressure mm HG &gt; 160 systolic &gt; 95 diastolic ) . 7 . Any history gastroparesis enteroparesis . 8 . Abnormal kidney and/ liver function test . ( Defined Creatinine &gt; 1.5 mg/dL , liver test &gt; 2 time upper limit normal ) . 9 . A severe hypoglycemic event require glucagon injection intravenous glucose infusion within last six month prior study inclusion . 10 . Hypoglycemia unawareness . 11 . Diabetic ketoacidosis ( severe , hospitalization ) within last six month prior study inclusion . 12 . Psychological incompetence . 13 . Signs drug abuse . 14 . Any clinical condition history , seem relevant Principle Investigator disqualify participant . 15 . Subjects diminish skin integrity , Excessive fibrosis , lipohypertrophy eczema infusion site . 16 . Heat sensitive subject . 17 . Subjects involve plan participate study . 18 . Subjects use drug therapy , insulin , control blood glucose level .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>MiniMed Paradigm insulin pump</keyword>
	<keyword>insulin Lispro</keyword>
	<keyword>Insulin Aspart</keyword>
	<keyword>Quick-set infusion set</keyword>
</DOC>